[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

France Cancer Diagnostics Market New Frontiers, Business Challenges, Emerging Technologies, Competitive Landscape

July 2016 | 585 pages | ID: FE004FBA6C5EN
Venture Planning Group

US$ 5,440.00 US$ 6,800.00 -20 %

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
Complete report $6,800. DataPack (test volumes, sales forecasts, supplier shares) $4,350.

VPGMarkets new report is a study of the major business opportunities emerging in the French cancer diagnostics market during the next five years. The report examines trends in the French cancer diagnostics markets, reviews current and emerging assays; analyzes potential applications of new diagnostic technologies; forecasts sales of major tumor markers by market segment; profiles leading players and potential market entrants; and identifies specific business opportunities for suppliers.

Rationale

The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. During the next five years, the worldwide cancer diagnostics market is promising to be an exciting, dynamic and rapidly expanding field. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy. The rise in geriatric population will further compound the growing demand for malignancy assays and the rapid market expansion worldwide.

France Market Overview
  • Five-year test volume and sales projections.
  • Comprehensive market segmentation analysis, including review of the market dynamics, structure, size, growth and major suppliers.
  • Estimated universe of laboratories performing cancer diagnostic testing.
  • Cancer statistics, etiology and recent developments.
Business Opportunities and Strategic Recommendations
  • Specific new product development opportunities with potentially significant market appeal during the next five years.
  • Design criteria for new products.
  • Alternative market penetration strategies.
  • Potential market entry barriers and risks.
Over 200 Current and Emerging Cancer Diagnostic Test
  • Biochemical Markers
  • Oncogenes
  • Growth Factors
  • Hormones
  • Colony Stimulating Factors
  • Lymphokines
  • Immunohistochemical Stains, and others.
  • ACTH, AFP, Beta-2 Microglobulin, CA 15-3/27.29, CA 19-9, CA 125, Calcitonin, Cathepsin, CEA, Chromogranin, Colon-Specific Antigen, Cytokeratins, Estrogen Receptor, Ferritin, Gastrin, HCG, Insulin, Interferons, Interleukins, Lymphocyte Subtyping, Neuron-Specific Enolase, Nucleolar, Occult Blood, Oncogenes, Pancreatic Oncofetal Antigen, Pap Smear, Parathyroid Hormone, Progesterone Receptor, Prostatic Acid Phosphatase, Prostatic Specific Antigen, S-100 Protein, Serotonin, Sialic Acid, Squamous Cell Carcinoma Ag, TDT, Thymidine Kinase, Thyroglobulin, Tissue Polypeptide Antigen, and others.
Supplier Shares, Sales and Volume Forecasts
  • Sales and market shares of major cancer diagnostic product suppliers by individual test.
  • Five-year test volume and sales forecasts for major tumor markers by market segment, including:
  • Hospitals
  • Commercial/Private Laboratories
Instrumentation Review
  • Analysis of major molecular diagnostic and immunodiagnostic analyzers used for cancer testing, including their operating characteristics, features and selling prices.
Technology Assessment
  • Assessment of latest molecular diagnostic methods, biochips/microarrays, biosensors, monoclonal antibodies, immunoassays, chromosome analysis, IT, artificial intelligence, flow cytometry, and other technologies and their potential applications for cancer diagnostic testing.
  • Review of competing/complementing technologies, including CT, MRI, NMR, PET and photonics spectroscopy.
  • Extensive listings of companies, universities and research centers developing new cancer diagnostic tests and detection technologies.
Competitive Strategies

Strategic assessments of major suppliers and start-up firms developing innovative technologies and products, including their sales, product portfolios, marketing tactics, collaborative arrangements, and new products in R&D.

The companies analyzed in the report include:
  • Abbott
  • AdnaGen
  • Agilent Technologies
  • Applied Gene Technologies
  • Arca Biopharma
  • Beckman Coulter/Danaher
  • Becton Dickinson
  • Biomedical Diagnostics
  • bioMerieux
  • Bio-Rad
  • CellSearch
  • Cepheid
  • Correlogic Systems/Vermillion
  • Decode Genetics
  • Diadexus
  • Diagnocure
  • DiaSorin
  • Eiken Chemical
  • Elitech Group
  • Enterix
  • Enzo Biochem
  • Epigenomics
  • Exact Sciences
  • Fujirebio
  • Guided Therapeutics
  • Hologic/Gen-Probe
  • Kreatech/Leica
  • Kyowa Medex
  • Mackay Life Sciences
  • Myriad Genetics
  • OncoLab
  • Ortho-Clinical Diagnostics
  • Panacea Pharmaceuticals
  • Polartechnics
  • Polymedco
  • PreMD
  • Qiagen
  • Quest Diagnostics
  • Radient Pharmaceuticals
  • Roche
  • Scienion
  • Sequenom
  • Siemens Healthcare
  • Takara Bio
  • Targeted Diagnostics & Therapeutics
  • Thermo Fisher
  • Tosoh
  • Veridex
  • Wako Pure Chemicals
  • Wallac/PE
  • Zilla
Contains 585 pages and 95 tables
1. INTRODUCTION

2. MAJOR PRODUCT DEVELOPMENT OPPORTUNITIES

    a. Reagent Kits and Test Systems/Panels
    b. INSTRUMENTATION

    c. Computers, Software and Automation
    d. Auxiliary Products

3. DESIGN CRITERIA FOR DECENTRALIZED TESTING PRODUCTS

4. ALTERNATIVE MARKET PENETRATION STRATEGIES

    a. Internal Development
    b. Collaborative Arrangements
    c. University Contracts
    d. Distribution Strategies
  1. MARKETING APPROACHES
  2. PRODUCT COMPLEXITY
  3. CUSTOMER PREFERENCE
  4. ESTABLISHED SUPPLIERS
  5. EMERGING SUPPLIERS
  6. MAJOR TYPES OF DISTRIBUTORS
  7. MARKET SEGMENTATION FACTOR

5. POTENTIAL MARKET ENTRY BARRIERS AND RISKS

    a. Market Maturity
    b. Cost Containment
    c. Competition
    d. Technological Edge and Limitations
    e. Patent Protection
    f. Regulatory Constraints
    g. Decentralized Testing Market Challenges

6. WORLDWIDE MARKET AND TECHNOLOGY OVERVIEW

    a. Cancer Statistics and Etiology
  1. BREAST CANCER
  2. LUNG CANCER
  3. COLON AND RECTUM CANCER
  4. PROSTATE CANCER
  5. STOMACH CANCER
  6. LEUKEMIA
  7. LYMPHOMA
  8. ORAL CANCER
  9. SKIN CANCER
  10. UTERINE CANCER
  11. OVARIAN CANCER
  12. BLADDER CANCER
    b. Major Current And Emerging Cancer Diagnostic Tests
  1. INTRODUCTION
  2. TUMOR MARKER CLASSIFICATION
  3. ACTH
  4. ALPHA  FETOPROTEIN (AFP)
  5. BETA  2 MICROGLOBULIN
  6. CA 15  3/27.29
  7. CA 19-
  8. CA-
  9. CALCITONIN
  10. CARCINOEMBRIONIC ANTIGEN (CEA)
  11. ESTROGEN AND PROGESTERONE RECEPTORS
  12. FERRITIN
  13. GASTRIN
  14. HUMAN CHORIONIC GONADOTROPIN (HCG)
  15. INSULIN
  16. NSE
  17. OCCULT BLOOD
  18. PAP SMEAR/HPV
  19. PROSTATIC ACID PHOSPHATASE (PAP)
  20. PROSTATe SPECIFIC ANTIGEN (PSA)
  21. SQUAMOUS CELL CARCINOMA ANTIGEN (SCC)
  22. T AND B LYMPHOCYTES
  23. TDT
  24. THYROGLOBULIN
  25. TISSUE POLYPEPTIDE ANTIGEN (TPA)
  26. BIOCHEMICAL TUMOR MARKERS
  ADA
  bProtein
  PNP
  5'  Nucleotidase
  27. ONCOGENES
  Abl/abl  bcr
  AIB1
  BCL-
  BRCA1
  CD44
  C fos
  C myb
  C myc
  CYP-
  ErbB
  HPC1
  nmyc
  P40
  P51
  P53
  PIK3CA
  PTI-
  Ras
  Reg
  Sis
  Src
  28. POLYPEPTIDE GROWTH FACTORS
  Basic Fibroblast Growth Factor
  Beta  TGF
  Cachectin (TNT)
  Calmodulin
  ECFR
  Nerve Growth Factor (NGF)
  Epidermal Growth Factor (EGF)
  Ornithine Decarboxylase
  Transferrin
  Transforming Growth Factor  Alpha
  29. ECTOPIC HORMONES
  30. COLONY STIMULATING FACTORS
  31. LYMPHOKINES
  Alpha  Interferon
  B Cell Growth Factors
  B Cell Growth Factor (BCGF)
  Gamma  Interferon
  Interleukin1 (IL  1)
  Macrophage Activating Factor
  32. IMMUNOHISTOCHEMICAL STAINS
  33. EMERGING TUMOR MARKERS
  nAcetylglucosamine
  Actin
  Alpha  Actin
  Antineuronal Antibodies
  7B2
  B72.3
  Bax
  BCD  F9
  BLCA-
  Blood Group Antigens A,B,H
  CA
  CA 72  4/TAG-
  CA
  CA-
  CA-
  CAM
  CAR-
  CathepsinD
  Chromogranin A and B
  Cluster 1 Antigen
  Cluster  5/5A Antigen
  CTA
  CU18
  DR-
  DU  PAN-
  Endometrial Bleeding Associated Factor
  Endostatin
  Epithelial Membrane Antigen
  Feulgen Hydrolysis
  Fibronectin
  FSH
  (1  >3)  L  fucosyltransferase
  GastrinReleasing Peptide (GRP)
  GDCFP-
  Glucagon
  Glycoamines
  H23
  Her-
  Human Carcinoma Antigen
  HPA
  HSP27
  Intermediate Filaments
  Cytokeratins/CK18/Cyfra 21-
  Desmin
  Gliofibrillary Acid Protein
  Neurofilaments
  Vimentin
  KA
  Kinases
  KP16D3
  LAI
  Leukocyte Common Antigen
  Lewis Antigens
  Lysophosphatidic Acid (LPA)
  Ma 695/Ma
  MABDF3
  MAG
  ME1
  Minactivin
  MN/CA9
  MSA
  Mucin Cancer Antigen (MCA)
  Multiple Tumor Suppressor
  Myosin
  NEA-
  NMP22
  OA-
  Opiod Peptides
  P glycoprotein
  Pancreatic Oncofetal Antigen (POA)
  Placental Lactogen
  PR92
  Proliferative Index, Ki-
  Px
  RB Inactivation/Deletion
  Ret
  SCCL
  Selectin
  Sialic Acid
  Sialyl SSEA  1/SLX
  SN10
  Somatostatin
  TA-
  TABA
  Tachykinin
  TAG
  TPS
  Troponin
  Tubulin
  VCAM
  VEGF
  Villen
    c. INSTRUMENTATION Review And Market Needs
    d. CURRENT AND EMERGING TECHNOLOGIES

  1. MOLECULAR DIAGNOSTICS
    a. Technology Overview
    b. Amplification Methods
    c. Sequencing
    d. Microarrays/Biochips
  2. MONOCLONAL AND POLYCLONAL ANTIBODIES
  3. IMMUNOASSAYS
    a. Technological Principle
    b. Radioimmunoassay (RIA)
    c. Enzyme Immunoassays (EIA)
  Overview
  ELISA
  Immunofiltration
  Particle Membrane Capture Immunoassay
  Enzyme Amplification
    d. Fluorescent Immunoassays
    e. Luminescence
  Chemiluminescence
  Bioluminescence
    f. Latex Agglutination
    g. Immunoprecipitation
    h. Affinity Chromatographu
    e. Liposome Flow  Injection Immunoassay
  4. CHROMOSOME ANALYSIS
    a. Chronic Myelogenous Leukemia (CML)
    b. Acute Myeloid Leukemia (AML)
    c. Acute Lymphoblastic Leukemia (ALL)
    d. Malignant Lymphomas Lymphoid Malignancies
    e. Chronic Lymphocytic Leukemia (CLL)
    f. Solid Cancers
    g. Chromosomal Translocation and Oncogenes
  5. ARTIFICIAL INTELLIGENCE
  6. FLOW CYTOMETRY
  7. TW      DIMENSIONAL GEL ELECTROPHORESIS (2  DGE)
  8. BIOSENSORS
  9. COMPETING/COMPLEMENTING TECHNOLOGIES
    a. CT
    b. MRI
    c. NMR
    d. PET
    e. Photonics Spectroscopy
    e. Personal Testing

7. FRANCE

    a. EXECUTIVE SUMMARY

    b. Business Environment
    c. Market Structure
    d. Market Size, Growth and Major Suppliers’ Sales and Market Shares

8. COMPETITIVE PROFILES

  Abbott
  AdnaGen
  Agilent Technologies
  Applied Gene Technologies
  Arca Biopharma
  Beckman Coulter/Danaher
  Becton Dickinson
  Biomedical Diagnostics
  bioMerieux
  Bio Rad
  CellSearch
  Cepheid
  Correlogic Systems/Vermillion
  Decode Genetics
  Diadexus
  Diagnocure
  Diasorin
  Eiken Chemical
  Elitech Group
  Epigenomics
  Enterix
  EnzBiochem
  Exact Sciences
  Fujirebio
  Guided Therapeutics
  Hologic/GenProbe
  Kreatech/Leica
  Kyowa Medex
  Mackay Life Sciences
  Myriad Genetics
  OncoLab
  Ortho Clinical Diagnostics
  Panacea Pharmaceuticals
  Polartechnics
  Polymedco
  PreMD
  Qiagen
  Quest Diagnostics
  Radient Pharmaceuticals
  Roche
  Scienion
  Sequenom
  Siemens Healthcare
  Takara Bio
  Targeted Diagnostics & Therapeutics
  ThermFisher
  Tosoh
  Veridex
  Wak      Pure Chemicals
  Wallac/PE
  Zila

9. APPENDIX: MAJOR UNIVERSITIES AND RESEARCH CENTERS DEVELOPING CANCER DIAGNOSTIC TECHNOLOGY AND APPLICATIONS

LIST OF TABLES

Tumor Marker Classification
Major Companies Developing or Marketing ACTH Tests
Major Companies Developing or Marketing AFP Tests
Major Companies Developing or Marketing Beta  2 Microglobulin Tests
Major Companies Developing or Marketing CA 15  3/27.29 Tests
Major Companies Developing or Marketing CA 19  9 Tests
Major Companies Developing or Marketing CA 125 Tests
Major Companies Developing or Marketing Calcitonin Tests
Major Companies Developing or Marketing CEA Tests
Major Companies Developing or Marketing Estrogen Receptor Tests
Major Companies Developing or Marketing Progesterone Receptor Tests
Major Companies Developing or Marketing Ferritin Tests
Major Companies Developing or Marketing Gastrin Tests
Major Companies Developing or Marketing HCG Tests
Major Companies Developing or Marketing Insulin Tests
Major Companies Developing or Marketing NSE Tests
Major Companies Developing or Marketing Occult Blood Tests
Major Companies Developing or Marketing PAP Smear/HPV Tests
Major Companies Developing or Marketing PAP Tests
Major Companies Developing or Marketing PSA Tests
Major Companies Developing or Marketing Lymphocyte Subclassification Tests
Biochemical Markers Potential Applications In Cancer Diagnosis
Oncogenes Potential Applications In Cancer Diagnosis
Major Companies Developing or Marketing Oncogene Tests
Growth Factors Potential Applications In Cancer Diagnosis
Colony Stimulating Factors Potential
Applications in Cancer Diagnosis
Lymphokines Potential Applications In Cancer Diagnosis
Immunohistochemical Stains Potential
Applications in Cancer Diagnosis
EXECUTIVE SUMMARY Table: France, Total Cancer Diagnostic Test Volume and Sales Forecast by Market Segment
France, Estimated Cancer Death Rates Per 100,000 Population
France, Laboratories Performing Tumor Marker Tests by Market Segment
France, Hospital Laboratories Performing Tumor Marker Tests by Bed Size
France, Commercial/Private Laboratories Performing Tumor MarKERS by Annual Test Volume
France, Total Tumor Marker Test Volume Forecast by Market Segment
France, All Market Segments Major Tumor Marker Test Volume Forecast
France, Hospital Laboratories Major Tumor Marker Test Volume Forecast by Test
France, Commercial/Private Laboratories Marker Test Volume Forecast
France, Total Tumor Marker Sales Major Tumor Forecast by Market Segment
France, All Market Segments Major Tumor Marker Sales Forecast by Test
France, Hospital Laboratories Major Tumor Marker Sales Forecast by Test
France, Commercial/Private Laboratories Cancer Diagnostics Market Forecast by Test
France, ACTH Test Volume and Diagnostics Sales Forecast by Market Segment
France, AFP Test Volume and Diagnostics Sales Forecast by Market Segment
France, Beta  2 Microglobulin Test Volume and Diagnostics Sales Forecast by Market Segment
France, CA 15  3/27.29 Test Volume and Diagnostics Sales Forecast by Market Segment
France, CA 19  9 Test Volume and Diagnostics Sales Forecast by Market
France, CA  125 Test Volume and Diagnostics Sales Forecast by Market Segment
France, Calcitonin Test Volume and Diagnostics Sales Forecast by Market Segment
France, Cathepsin Test Volume and Diagnostics Sales Forecast by Market Segment
France, CEA Test Volume and Diagnostics Sales Forecast by Market Segment
France, ColonSpecific Antigen Test Volume and Diagnostics Sales Forecast by Market Segment
France, Cytokeratins Test Volume and Diagnostics Sales Forecast by Market Segment
France, Estrogen Receptor Test Volume and Diagnostics Sales Forecast by Market Segment
France, Ferritin Test Volume and Diagnostics Sales Forecast by Market Segment
France, Gastrin Test Volume and Diagnostics Sales Forecast by Market Segment
France, HCG Test Volume and Diagnostics Sales Forecast by Market Segment
France, Insulin Test Volume and Diagnostics Sales Forecast by Market Segment
France, Interferons Test Volume and Diagnostics Sales Forecast by Market Segment
France, Interleukins Test Volume and Diagnostics Sales Forecast by Market Segment
France, Lymphocyte Subtyping Test Volume and Diagnostics Sales Forecast by Market Segment
France, NSE Test Volume and Diagnostics Sales Forecast by Market Segment
France, Nucleolar Test Volume and Diagnostics Sales Forecast by Market Segment
France, Occult Blood Test Volume and Diagnostics Sales Forecast by Market Segment
France, Oncogenes Test Volume and Diagnostics Sales Forecast by Market Segment
France, Pancreatic Oncofetal Antigen Test Volume and Diagnostics Sales Forecast by Market Segment
France, PAP Smear Test Volume and Diagnostics Sales Forecast by Market Segment
France, Parathyroid Hormone Test Volume and Diagnostics Sales Forecast by Market Segment
France, Progesterone Receptor Test Volume and Diagnostics Sales Forecast by Market Segment
France, PAP Test Volume and Diagnostics Sales Forecast by Market Segment
France, PSA Test Volume and Diagnostics Sales Forecast by Market Segment
France, S  100 Protein Test Volume and Sales
Diagnostics Sales Forecast by Market Segment
France, Serotonin Test Volume and Diagnostics Sales Forecast by Market Segment
France, Sialic Acid Test Volume and Diagnostics Sales Forecast by Market Segment
France, Squamous Cell Carcinoma Antigen Test Volume and Diagnostics Sales Forecast by Market Segment
France, TDT Test Volume and Diagnostics Sales Forecast by Market Segment
France, Thymidine Kinase Test Volume and Diagnostics Sales Forecast by Market Segment
France, Thyroglobulin Test Volume and Diagnostics Sales Forecast by Market Segment
France, TPA Test Volume and Diagnostics Sales Forecast by Market Segment
France, Total Tumor Marker Sales by Major Suppliers
France, AFP Testing Market Diagnostics Sales by Major Supplier
France, CA 15  3 Testing Market Diagnostics Sales by Major Supplier
France, CA 19  9 Testing Market Diagnostics Sales by Major Supplier
France, CA 125 Testing Market Diagnostics Sales by Major Supplier
France, CEA Testing Market Diagnostics Sales by Major Supplier
France, NSE Testing Market Diagnostics Sales by Major Supplier
France, PAP Testing Market Diagnostics Sales by Major Supplier
France, PSA Testing Market Diagnostics Sales by Major Supplier


More Publications